Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition

C. Genovese, Mark; Becker, Jean‐Claude; Schiff, Michael; E. Luggen, Michael; Sherrer, Yvonne; Kremer, Joel; Birbara, C.; Box, J.; Natarajan, Kannan; Nuamah, Isaac; Li, Tracy; Aranda, Richard; Hagerty, David; Dougados, Maxime

doi:10.1056/nejmoa050524

Public

Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition

Published in New England Journal of Medicine • Sep 14, 2005

Authors:

Mark C. Genovese

Jean‐Claude Becker

Michael Schiff

Abstract

BACKGROUND: A substantial number of patients with rheumatoid arthritis have an inadequate or unsustained response to tumor necrosis factor alpha (TNF-alpha) inhibitors. We conducted a randomized, double-blind, phase 3 trial to evaluate the efficacy and safety of abatacept, a selective costimulation ...

Subject

Medicine

Abatacept

Rheumatoid arthritis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!